<DOC>
	<DOCNO>NCT00652899</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , cyclophosphamide fludarabine , total-body irradiation donor natural killer cell infusion help stop growth tumor cell . It also help stop patient 's immune system reject donor 's natural killer cell . Aldesleukin may stimulate natural killer cell kill ovarian , fallopian tube , primary peritoneal cancer cell . Treating donor natural killer cell aldesleukin may help natural killer cell kill tumor cell . PURPOSE : This phase II trial study well give laboratory-treated donor natural killer cell together aldesleukin work give cyclophosphamide , fludarabine , total-body irradiation treat patient recurrent and/or metastatic ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Allogeneic Natural Killer Cells Patients With Recurrent Ovarian Cancer , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate vivo expansion infuse allogeneic natural killer ( NK ) cell product follow preparative regimen comprise cyclophosphamide , fludarabine phosphate , total-body irradiation treat patient recurrent and/or metastatic ovarian , fallopian tube , primary peritoneal cancer . Secondary - To characterize quantitative qualitative toxicity treatment regimen . - To estimate disease response ( complete partial response ) clinical benefit ( stable disease &gt; 6 month ) measure Response Evaluation Criteria Solid Tumours ( RECIST ) criterion . - To estimate time progression overall survival . - To estimate association clinical response donor/recipient KIR ligand match status . Tertiary - To evaluate immune activation vivo expand haploidentical allogeneic NK cell effect immune system . OUTLINE : - Preparative regimen : Patients receive fludarabine phosphate IV day 6 2 precede natural killer ( NK ) cell infusion cyclophosphamide IV day 5 4 precede NK cell infusion . Patients also undergo total-body irradiation day 1 precede NK cell infusion . - Allogeneic natural killer ( NK ) cell administration aldesleukin : Patients receive aldesleukin-activated haploidentical allogeneic NK cell intravenously ( IV ) day 0 . Beginning 4-6 hour allogeneic NK cell infusion , patient receive aldesleukin subcutaneously ( SC ) 3 time week 6 dos . Patients achieve initial response ( complete partial response ) clinical benefit ( stable disease &gt; 6 month ) progress 6 month may receive 1 re-treatment course . Blood sample collect baseline , day 0 , 7 , 14 , 28 , 2 3 month post NK cell infusion cytokine measurement , immunophenotyping , functional analysis , test persistence donor cell . After completion study treatment , patient follow periodically least 1 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis recurrent ovarian cancer , fallopian tube , primary peritoneal cancer meet follow criterion : Measurable disease ( ≥ 1 cm ) per Response Evaluation Criteria Solid Tumors ( RECIST ) patient bone site metastatic disease eligible Progression failure respond least 2 salvage chemotherapy regimen ( 2 regimen give disease recurrence ) recurrent/metastatic ovarian , fallopian tube , primary peritoneal cancer If history brain metastasis , stable least 3 month treatment A brain compute tomography ( CT ) scan require subject know brain metastasis time enrollment subject new clinical sign symptom suggestive brain metastasis . Available related HLAhaploidentical natural killer ( NK ) cell donor ( least class I serologic type ) . If biologic parent sibling available , proceed workup subject prior return human leukocyte antigen ( HLA ) type result . Age 18 year old Gynecology Oncology Group ( GOG ) performance status 0 1 Adequate organ function determine follow criterion within 14 day study enrollment : Bone marrow : platelet ≥ 80,000 x 10^9/L hemoglobin ≥ 9g/dL , unsupported transfusion ; absolute neutrophil count ( ANC ) ≥ 1000 x 10^9/L , unsupported granulocytecolony stimulate factor ( GCSF ) granulocyte macrophagecolony stimulate factor ( GMCSF ) Renal function : creatinine ( Cr ) ≤ 2.0 mg/dL Liver function : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase &lt; 5 time upper limit institutional normal Cardiac : Left ventricular ejection fraction &gt; 40 % Pulmonary function : &gt; 50 % correct Carbon Monoxide Diffusing Capacity ( DLCO ) Forced expiratory volume one second ( FEV1 ) , presence pleural effusion due metastatic disease &gt; 40 % correct DLCO FEV1 acceptable . Able prednisone immunosuppressive medication least 3 day prior Day 0 Voluntary write informed consent sign performance study relate procedure part normal medical care . Pregnant lactate The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 14 day prior registration rule pregnancy . Active infection subject must afebrile , antibiotic , uninvestigated radiologic lesion ( infiltrates lesion negative culture biopsy allow ) . Human antimouse antibody ( HAMA ) monitoring : All subject question prior exposure antibody therapy ( include OKT3 , Rituximab , Trastuzumab , etc ) . Responses record report FDA part annual report . For subject prior antibody therapy exposure , action take . For subject receive previous antibody therapy 10 ml serum ( red top tube ) drawn start therapy bank per section 8.1 . The presence HAMA exclude patient study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>